#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=8. Complications of LVADs
1-1	0-2	8.	_	_	_	_
1-2	3-16	Complications	abstract[1]	new[1]	coref	4-1[14_1]
1-3	17-19	of	abstract[1]	new[1]	_	_
1-4	20-25	LVADs	abstract[1]|abstract	new[1]|new	coref	5-14

#Text=While survival has improved with CF-LVADS , the adverse event profile remains high .
2-1	26-31	While	_	_	_	_
2-2	32-40	survival	event	new	_	_
2-3	41-44	has	_	_	_	_
2-4	45-53	improved	_	_	_	_
2-5	54-58	with	_	_	_	_
2-6	59-67	CF-LVADS	substance	new	_	_
2-7	68-69	,	_	_	_	_
2-8	70-73	the	abstract[6]	new[6]	_	_
2-9	74-81	adverse	abstract[6]	new[6]	_	_
2-10	82-87	event	event|abstract[6]	new|new[6]	_	_
2-11	88-95	profile	abstract[6]	new[6]	_	_
2-12	96-103	remains	_	_	_	_
2-13	104-108	high	_	_	_	_
2-14	109-110	.	_	_	_	_

#Text=At 1 month post-implant , nearly 30 % and at 1 year , almost 80 % of patients , require readmission .
3-1	111-113	At	_	_	_	_
3-2	114-115	1	time[7]|object[8]	new[7]|new[8]	_	_
3-3	116-121	month	time[7]|object[8]	new[7]|new[8]	_	_
3-4	122-134	post-implant	object[8]	new[8]	_	_
3-5	135-136	,	_	_	_	_
3-6	137-143	nearly	quantity[9]	new[9]	_	_
3-7	144-146	30	quantity[9]	new[9]	_	_
3-8	147-148	%	quantity[9]	new[9]	_	_
3-9	149-152	and	_	_	_	_
3-10	153-155	at	_	_	_	_
3-11	156-157	1	time[10]|quantity[11]	new[10]|new[11]	_	_
3-12	158-162	year	time[10]|quantity[11]	new[10]|new[11]	_	_
3-13	163-164	,	quantity[11]	new[11]	_	_
3-14	165-171	almost	quantity[11]	new[11]	_	_
3-15	172-174	80	quantity[11]	new[11]	_	_
3-16	175-176	%	quantity[11]	new[11]	_	_
3-17	177-179	of	quantity[11]	new[11]	_	_
3-18	180-188	patients	quantity[11]|person	new[11]|new	coref	5-12[21_0]
3-19	189-190	,	_	_	_	_
3-20	191-198	require	_	_	_	_
3-21	199-210	readmission	abstract	new	_	_
3-22	211-212	.	_	_	_	_

#Text=The common LVAD-related complications , outside of the immediate post-operative period , are outlined in Table 4 .
4-1	213-216	The	abstract[14]	giv[14]	coref	6-4[25_14]
4-2	217-223	common	abstract[14]	giv[14]	_	_
4-3	224-236	LVAD-related	abstract[14]	giv[14]	_	_
4-4	237-250	complications	abstract[14]	giv[14]	_	_
4-5	251-252	,	abstract[14]	giv[14]	_	_
4-6	253-260	outside	abstract[14]	giv[14]	_	_
4-7	261-263	of	abstract[14]	giv[14]	_	_
4-8	264-267	the	abstract[14]|time[15]	giv[14]|new[15]	_	_
4-9	268-277	immediate	abstract[14]|time[15]	giv[14]|new[15]	_	_
4-10	278-292	post-operative	abstract[14]|time[15]	giv[14]|new[15]	_	_
4-11	293-299	period	abstract[14]|time[15]	giv[14]|new[15]	_	_
4-12	300-301	,	_	_	_	_
4-13	302-305	are	_	_	_	_
4-14	306-314	outlined	_	_	_	_
4-15	315-317	in	_	_	_	_
4-16	318-323	Table	abstract|abstract[17]	new|new[17]	_	_
4-17	324-325	4	abstract[17]	new[17]	_	_
4-18	326-327	.	_	_	_	_

#Text=Providers in the community may be the first medical contact for patients with LVADs experiencing a complication .
5-1	328-337	Providers	person[18]	new[18]	_	_
5-2	338-340	in	person[18]	new[18]	_	_
5-3	341-344	the	person[18]|place[19]	new[18]|new[19]	_	_
5-4	345-354	community	person[18]|place[19]	new[18]|new[19]	_	_
5-5	355-358	may	_	_	_	_
5-6	359-361	be	_	_	_	_
5-7	362-365	the	abstract[20]	new[20]	_	_
5-8	366-371	first	abstract[20]	new[20]	_	_
5-9	372-379	medical	abstract[20]	new[20]	_	_
5-10	380-387	contact	abstract[20]	new[20]	_	_
5-11	388-391	for	abstract[20]	new[20]	_	_
5-12	392-400	patients	abstract[20]|person[21]	new[20]|giv[21]	coref	12-5[52_21]
5-13	401-405	with	abstract[20]|person[21]	new[20]|giv[21]	_	_
5-14	406-411	LVADs	abstract[20]|person[21]|object	new[20]|giv[21]|giv	coref	10-19
5-15	412-424	experiencing	_	_	_	_
5-16	425-426	a	abstract[23]	new[23]	_	_
5-17	427-439	complication	abstract[23]	new[23]	_	_
5-18	440-441	.	_	_	_	_

#Text=Though management of these complications should be in concert with LVAD specialists , an awareness and understanding of the common complications can help with timely diagnosis and therapeutic intervention .
6-1	442-448	Though	_	_	_	_
6-2	449-459	management	abstract[24]	new[24]	_	_
6-3	460-462	of	abstract[24]	new[24]	_	_
6-4	463-468	these	abstract[24]|abstract[25]	new[24]|giv[25]	coref	6-19[31_25]
6-5	469-482	complications	abstract[24]|abstract[25]	new[24]|giv[25]	_	_
6-6	483-489	should	_	_	_	_
6-7	490-492	be	_	_	_	_
6-8	493-495	in	_	_	_	_
6-9	496-503	concert	event[26]	new[26]	_	_
6-10	504-508	with	event[26]	new[26]	_	_
6-11	509-513	LVAD	event[26]|object|person[28]	new[26]|new|new[28]	coref	8-1
6-12	514-525	specialists	event[26]|person[28]	new[26]|new[28]	_	_
6-13	526-527	,	_	_	_	_
6-14	528-530	an	abstract[29]	new[29]	_	_
6-15	531-540	awareness	abstract[29]	new[29]	_	_
6-16	541-544	and	_	_	_	_
6-17	545-558	understanding	abstract[30]	new[30]	_	_
6-18	559-561	of	abstract[30]	new[30]	_	_
6-19	562-565	the	abstract[30]|abstract[31]	new[30]|giv[31]	_	_
6-20	566-572	common	abstract[30]|abstract[31]	new[30]|giv[31]	_	_
6-21	573-586	complications	abstract[30]|abstract[31]	new[30]|giv[31]	_	_
6-22	587-590	can	_	_	_	_
6-23	591-595	help	_	_	_	_
6-24	596-600	with	_	_	_	_
6-25	601-607	timely	abstract[32]	new[32]	_	_
6-26	608-617	diagnosis	abstract[32]	new[32]	_	_
6-27	618-621	and	_	_	_	_
6-28	622-633	therapeutic	event[33]	new[33]	_	_
6-29	634-646	intervention	event[33]	new[33]	_	_
6-30	647-648	.	_	_	_	_

#Text=8.1 .
7-1	649-652	8.1	abstract	new	_	_
7-2	653-654	.	_	_	_	_

#Text=LVAD
8-1	655-659	LVAD	abstract	giv	coref	11-4[47_0]

#Text=Infections
9-1	660-670	Infections	abstract	new	coref	10-13

#Text=Due to the presence of a percutaneous driveline exiting the skin , infections remain the Achilles heel of LVADs .
10-1	671-674	Due	_	_	_	_
10-2	675-677	to	_	_	_	_
10-3	678-681	the	abstract[37]	new[37]	coref	19-30[127_37]
10-4	682-690	presence	abstract[37]	new[37]	_	_
10-5	691-693	of	abstract[37]	new[37]	_	_
10-6	694-695	a	abstract[37]|abstract[38]	new[37]|new[38]	coref	12-19[57_38]
10-7	696-708	percutaneous	abstract[37]|abstract[38]	new[37]|new[38]	_	_
10-8	709-718	driveline	abstract[37]|abstract[38]	new[37]|new[38]	_	_
10-9	719-726	exiting	_	_	_	_
10-10	727-730	the	object[39]	new[39]	coref	21-4[0_39]
10-11	731-735	skin	object[39]	new[39]	_	_
10-12	736-737	,	_	_	_	_
10-13	738-748	infections	event	giv	coref	12-3[50_0]
10-14	749-755	remain	_	_	_	_
10-15	756-759	the	abstract[42]	new[42]	_	_
10-16	760-768	Achilles	person|abstract[42]	new|new[42]	_	_
10-17	769-773	heel	abstract[42]	new[42]	_	_
10-18	774-776	of	abstract[42]	new[42]	_	_
10-19	777-782	LVADs	abstract[42]|abstract	new[42]|giv	coref	33-12
10-20	783-784	.	_	_	_	_

#Text=Recent implantation of the first-in-man totally implantable LVAD aims to minimize this risk .
11-1	785-791	Recent	event[44]	new[44]	_	_
11-2	792-804	implantation	event[44]	new[44]	_	_
11-3	805-807	of	event[44]	new[44]	_	_
11-4	808-811	the	event[44]|object[47]	new[44]|giv[47]	coref	12-5[0_47]
11-5	812-824	first-in-man	event[44]|person|object[47]	new[44]|new|giv[47]	_	_
11-6	825-832	totally	event[44]|abstract[46]|object[47]	new[44]|new[46]|giv[47]	_	_
11-7	833-844	implantable	event[44]|abstract[46]|object[47]	new[44]|new[46]|giv[47]	_	_
11-8	845-849	LVAD	event[44]|object[47]	new[44]|giv[47]	_	_
11-9	850-854	aims	_	_	_	_
11-10	855-857	to	_	_	_	_
11-11	858-866	minimize	_	_	_	_
11-12	867-871	this	abstract[48]	new[48]	coref	15-14[90_48]
11-13	872-876	risk	abstract[48]	new[48]	_	_
11-14	877-878	.	_	_	_	_

#Text=ISHLT classifies infections in LVAD patients as VAD-specific ( involving the pump , cannula , pocket , or percutaneous driveline ) , VAD-related ( infective endocarditis , blood stream infections including central venous catheter associated , mediastinitis ) and non-VAD infections such as pneumonia .
12-1	879-884	ISHLT	organization	new	_	_
12-2	885-895	classifies	_	_	_	_
12-3	896-906	infections	event[50]	giv[50]	coref	12-28[60_50]
12-4	907-909	in	event[50]	giv[50]	_	_
12-5	910-914	LVAD	event[50]|abstract|person[52]	giv[50]|giv|giv[52]	coref|coref	17-24|20-13[137_52]
12-6	915-923	patients	event[50]|person[52]	giv[50]|giv[52]	_	_
12-7	924-926	as	event[50]|person[52]	giv[50]|giv[52]	_	_
12-8	927-939	VAD-specific	event[50]|person[52]	giv[50]|giv[52]	_	_
12-9	940-941	(	_	_	_	_
12-10	942-951	involving	_	_	_	_
12-11	952-955	the	object[53]	new[53]	coref	30-4[0_53]
12-12	956-960	pump	object[53]	new[53]	_	_
12-13	961-962	,	_	_	_	_
12-14	963-970	cannula	object	new	_	_
12-15	971-972	,	_	_	_	_
12-16	973-979	pocket	object	new	_	_
12-17	980-981	,	_	_	_	_
12-18	982-984	or	_	_	_	_
12-19	985-997	percutaneous	person|abstract[57]	new|giv[57]	coref	14-4[0_57]
12-20	998-1007	driveline	abstract[57]	giv[57]	_	_
12-21	1008-1009	)	_	_	_	_
12-22	1010-1011	,	_	_	_	_
12-23	1012-1023	VAD-related	_	_	_	_
12-24	1024-1025	(	_	_	_	_
12-25	1026-1035	infective	abstract[58]	new[58]	_	_
12-26	1036-1048	endocarditis	abstract[58]	new[58]	_	_
12-27	1049-1050	,	_	_	_	_
12-28	1051-1056	blood	event[60]	giv[60]	coref	12-40[64_60]
12-29	1057-1063	stream	abstract|event[60]	new|giv[60]	_	_
12-30	1064-1074	infections	event[60]	giv[60]	_	_
12-31	1075-1084	including	event[60]	giv[60]	_	_
12-32	1085-1092	central	event[60]|object[62]	giv[60]|new[62]	_	_
12-33	1093-1099	venous	event[60]|person|object[62]	giv[60]|new|new[62]	_	_
12-34	1100-1108	catheter	event[60]|object[62]	giv[60]|new[62]	_	_
12-35	1109-1119	associated	_	_	_	_
12-36	1120-1121	,	_	_	_	_
12-37	1122-1135	mediastinitis	object	new	_	_
12-38	1136-1137	)	_	_	_	_
12-39	1138-1141	and	_	_	_	_
12-40	1142-1149	non-VAD	event[64]	giv[64]	coref	20-8[135_64]
12-41	1150-1160	infections	event[64]	giv[64]	_	_
12-42	1161-1165	such	event[64]	giv[64]	_	_
12-43	1166-1168	as	event[64]	giv[64]	_	_
12-44	1169-1178	pneumonia	event[64]|abstract	giv[64]|new	_	_
12-45	1179-1180	.	_	_	_	_

#Text=Different techniques , largely limited to single-center experiences , have been shown to reduce infection rates and there is no universal protocol .
13-1	1181-1190	Different	abstract[66]	new[66]	_	_
13-2	1191-1201	techniques	abstract[66]	new[66]	_	_
13-3	1202-1203	,	_	_	_	_
13-4	1204-1211	largely	_	_	_	_
13-5	1212-1219	limited	_	_	_	_
13-6	1220-1222	to	_	_	_	_
13-7	1223-1236	single-center	abstract[67]	new[67]	_	_
13-8	1237-1248	experiences	abstract[67]	new[67]	_	_
13-9	1249-1250	,	_	_	_	_
13-10	1251-1255	have	_	_	_	_
13-11	1256-1260	been	_	_	_	_
13-12	1261-1266	shown	_	_	_	_
13-13	1267-1269	to	_	_	_	_
13-14	1270-1276	reduce	_	_	_	_
13-15	1277-1286	infection	abstract|abstract[69]	new|new[69]	coref	14-4[74_0]
13-16	1287-1292	rates	abstract[69]	new[69]	_	_
13-17	1293-1296	and	_	_	_	_
13-18	1297-1302	there	_	_	_	_
13-19	1303-1305	is	_	_	_	_
13-20	1306-1308	no	abstract[70]	new[70]	_	_
13-21	1309-1318	universal	abstract[70]	new[70]	_	_
13-22	1319-1327	protocol	abstract[70]	new[70]	_	_
13-23	1328-1329	.	_	_	_	_

#Text=Risk factors for driveline infection include trauma to the driveline exit site , younger age , higher body mass index and exposed driveline velour .
14-1	1330-1334	Risk	person|abstract[72]	new|new[72]	_	_
14-2	1335-1342	factors	abstract[72]	new[72]	_	_
14-3	1343-1346	for	abstract[72]	new[72]	_	_
14-4	1347-1356	driveline	abstract[72]|abstract|abstract[74]	new[72]|giv|giv[74]	coref|coref	14-10|15-17[0_74]
14-5	1357-1366	infection	abstract[72]|abstract[74]	new[72]|giv[74]	_	_
14-6	1367-1374	include	_	_	_	_
14-7	1375-1381	trauma	event[75]	new[75]	_	_
14-8	1382-1384	to	event[75]	new[75]	_	_
14-9	1385-1388	the	event[75]|place[78]	new[75]|new[78]	coref	15-1[85_78]
14-10	1389-1398	driveline	event[75]|abstract|place[78]	new[75]|giv|new[78]	coref	14-23
14-11	1399-1403	exit	event[75]|abstract|place[78]	new[75]|new|new[78]	coref	15-2
14-12	1404-1408	site	event[75]|place[78]	new[75]|new[78]	_	_
14-13	1409-1410	,	_	_	_	_
14-14	1411-1418	younger	abstract[79]	new[79]	coref	32-14[0_79]
14-15	1419-1422	age	abstract[79]	new[79]	_	_
14-16	1423-1424	,	_	_	_	_
14-17	1425-1431	higher	quantity[82]	new[82]	_	_
14-18	1432-1436	body	object|quantity[82]	new|new[82]	_	_
14-19	1437-1441	mass	quantity|quantity[82]	new|new[82]	_	_
14-20	1442-1447	index	quantity[82]	new[82]	_	_
14-21	1448-1451	and	_	_	_	_
14-22	1452-1459	exposed	_	_	_	_
14-23	1460-1469	driveline	abstract	giv	coref	15-5
14-24	1470-1476	velour	_	_	_	_
14-25	1477-1478	.	_	_	_	_

#Text=Meticulous exit site and driveline care and driveline immobilization are advised to reduce the risk of infection .
15-1	1479-1489	Meticulous	place[85]	giv[85]	coref	17-8[0_85]
15-2	1490-1494	exit	abstract|place[85]	giv|giv[85]	coref	23-8
15-3	1495-1499	site	place[85]	giv[85]	_	_
15-4	1500-1503	and	_	_	_	_
15-5	1504-1513	driveline	abstract|abstract[87]	giv|new[87]	coref|coref	15-8|17-30[0_87]
15-6	1514-1518	care	abstract[87]	new[87]	_	_
15-7	1519-1522	and	_	_	_	_
15-8	1523-1532	driveline	abstract|event[89]	giv|new[89]	coref	16-1
15-9	1533-1547	immobilization	event[89]	new[89]	_	_
15-10	1548-1551	are	_	_	_	_
15-11	1552-1559	advised	_	_	_	_
15-12	1560-1562	to	_	_	_	_
15-13	1563-1569	reduce	_	_	_	_
15-14	1570-1573	the	abstract[90]	giv[90]	_	_
15-15	1574-1578	risk	abstract[90]	giv[90]	_	_
15-16	1579-1581	of	abstract[90]	giv[90]	_	_
15-17	1582-1591	infection	abstract[90]|abstract	giv[90]|giv	coref	23-18[155_0]
15-18	1592-1593	.	_	_	_	_

#Text=Driveline drainage culture and blood cultures should be obtained , and imaging may be needed as well .
16-1	1594-1603	Driveline	abstract|abstract[94]	giv|new[94]	coref|coref	17-7|18-1[115_94]
16-2	1604-1612	drainage	event|abstract[94]	new|new[94]	coref	17-14[104_0]
16-3	1613-1620	culture	abstract[94]	new[94]	_	_
16-4	1621-1624	and	_	_	_	_
16-5	1625-1630	blood	substance|object[96]	new|new[96]	coref|coref	20-1|20-1[133_96]
16-6	1631-1639	cultures	object[96]	new[96]	_	_
16-7	1640-1646	should	_	_	_	_
16-8	1647-1649	be	_	_	_	_
16-9	1650-1658	obtained	_	_	_	_
16-10	1659-1660	,	_	_	_	_
16-11	1661-1664	and	_	_	_	_
16-12	1665-1672	imaging	event	new	_	_
16-13	1673-1676	may	_	_	_	_
16-14	1677-1679	be	_	_	_	_
16-15	1680-1686	needed	_	_	_	_
16-16	1687-1689	as	_	_	_	_
16-17	1690-1694	well	_	_	_	_
16-18	1695-1696	.	_	_	_	_

#Text=It is important to note that driveline site assessment and obtaining specimens of the drainage should only be performed by members of the LVAD team ( or designated shared care centers ) in order to limit the number of times and the number of people to whom the driveline is exposed .
17-1	1697-1699	It	abstract	new	cata	17-1[0_99]
17-2	1700-1702	is	_	_	_	_
17-3	1703-1712	important	_	_	_	_
17-4	1713-1715	to	abstract[99]	new[99]	_	_
17-5	1716-1720	note	abstract[99]	new[99]	_	_
17-6	1721-1725	that	abstract[99]	new[99]	_	_
17-7	1726-1735	driveline	abstract[99]|abstract|abstract[102]	new[99]|giv|new[102]	coref	17-48[114_0]
17-8	1736-1740	site	abstract[99]|place|abstract[102]	new[99]|giv|new[102]	coref	19-7[120_0]
17-9	1741-1751	assessment	abstract[99]|abstract[102]	new[99]|new[102]	_	_
17-10	1752-1755	and	abstract[99]	new[99]	_	_
17-11	1756-1765	obtaining	abstract[99]	new[99]	_	_
17-12	1766-1775	specimens	abstract[99]|object[103]	new[99]|new[103]	_	_
17-13	1776-1778	of	abstract[99]|object[103]	new[99]|new[103]	_	_
17-14	1779-1782	the	abstract[99]|object[103]|event[104]	new[99]|new[103]|giv[104]	coref	18-3[116_104]
17-15	1783-1791	drainage	abstract[99]|object[103]|event[104]	new[99]|new[103]|giv[104]	_	_
17-16	1792-1798	should	abstract[99]	new[99]	_	_
17-17	1799-1803	only	abstract[99]	new[99]	_	_
17-18	1804-1806	be	abstract[99]	new[99]	_	_
17-19	1807-1816	performed	abstract[99]	new[99]	_	_
17-20	1817-1819	by	_	_	_	_
17-21	1820-1827	members	person[105]	new[105]	_	_
17-22	1828-1830	of	person[105]	new[105]	_	_
17-23	1831-1834	the	person[105]|person[107]	new[105]|new[107]	coref	23-26[156_107]
17-24	1835-1839	LVAD	person[105]|event|person[107]	new[105]|giv|new[107]	coref	20-13
17-25	1840-1844	team	person[105]|person[107]	new[105]|new[107]	_	_
17-26	1845-1846	(	_	_	_	_
17-27	1847-1849	or	_	_	_	_
17-28	1850-1860	designated	place[109]	new[109]	_	_
17-29	1861-1867	shared	place[109]	new[109]	_	_
17-30	1868-1872	care	abstract|place[109]	giv|new[109]	_	_
17-31	1873-1880	centers	place[109]	new[109]	_	_
17-32	1881-1882	)	_	_	_	_
17-33	1883-1885	in	_	_	_	_
17-34	1886-1891	order	_	_	_	_
17-35	1892-1894	to	_	_	_	_
17-36	1895-1900	limit	_	_	_	_
17-37	1901-1904	the	time[110]	new[110]	_	_
17-38	1905-1911	number	time[110]	new[110]	_	_
17-39	1912-1914	of	time[110]	new[110]	_	_
17-40	1915-1920	times	time[110]|time	new[110]|new	_	_
17-41	1921-1924	and	_	_	_	_
17-42	1925-1928	the	quantity[112]	new[112]	_	_
17-43	1929-1935	number	quantity[112]	new[112]	_	_
17-44	1936-1938	of	quantity[112]	new[112]	_	_
17-45	1939-1945	people	quantity[112]|person[113]	new[112]|new[113]	_	_
17-46	1946-1948	to	quantity[112]|person[113]	new[112]|new[113]	_	_
17-47	1949-1953	whom	quantity[112]|person[113]	new[112]|new[113]	_	_
17-48	1954-1957	the	abstract[114]	giv[114]	coref	19-8[0_114]
17-49	1958-1967	driveline	abstract[114]	giv[114]	_	_
17-50	1968-1970	is	_	_	_	_
17-51	1971-1978	exposed	_	_	_	_
17-52	1979-1980	.	_	_	_	_

#Text=Culture of any drainage is recommended .
18-1	1981-1988	Culture	abstract[115]	giv[115]	_	_
18-2	1989-1991	of	abstract[115]	giv[115]	_	_
18-3	1992-1995	any	abstract[115]|event[116]	giv[115]|giv[116]	_	_
18-4	1996-2004	drainage	abstract[115]|event[116]	giv[115]|giv[116]	_	_
18-5	2005-2007	is	_	_	_	_
18-6	2008-2019	recommended	_	_	_	_
18-7	2020-2021	.	_	_	_	_

#Text=Abnormal swelling of the region surrounding the driveline site should be assessed by imaging studies ( i. e. , ultrasound , CT scan or PET scan ) to assess the presence , extent , and appearance of any fluid collections .
19-1	2022-2030	Abnormal	abstract[117]	new[117]	_	_
19-2	2031-2039	swelling	abstract[117]	new[117]	_	_
19-3	2040-2042	of	abstract[117]	new[117]	_	_
19-4	2043-2046	the	abstract[117]|place[118]	new[117]|new[118]	_	_
19-5	2047-2053	region	abstract[117]|place[118]	new[117]|new[118]	_	_
19-6	2054-2065	surrounding	_	_	_	_
19-7	2066-2069	the	place[120]	giv[120]	coref	23-6[153_120]
19-8	2070-2079	driveline	abstract|place[120]	giv|giv[120]	coref	23-7
19-9	2080-2084	site	place[120]	giv[120]	_	_
19-10	2085-2091	should	_	_	_	_
19-11	2092-2094	be	_	_	_	_
19-12	2095-2103	assessed	_	_	_	_
19-13	2104-2106	by	_	_	_	_
19-14	2107-2114	imaging	_	_	_	_
19-15	2115-2122	studies	event	new	coref	32-1[212_0]
19-16	2123-2124	(	_	_	_	_
19-17	2125-2127	i.	_	_	_	_
19-18	2128-2130	e.	_	_	_	_
19-19	2131-2132	,	_	_	_	_
19-20	2133-2143	ultrasound	abstract	new	_	_
19-21	2144-2145	,	_	_	_	_
19-22	2146-2148	CT	abstract|object[124]	new|new[124]	coref	25-11[168_0]
19-23	2149-2153	scan	object[124]	new[124]	_	_
19-24	2154-2156	or	_	_	_	_
19-25	2157-2160	PET	animal|object[126]	new|new[126]	coref	26-7
19-26	2161-2165	scan	object[126]	new[126]	_	_
19-27	2166-2167	)	_	_	_	_
19-28	2168-2170	to	_	_	_	_
19-29	2171-2177	assess	_	_	_	_
19-30	2178-2181	the	abstract[127]	giv[127]	_	_
19-31	2182-2190	presence	abstract[127]	giv[127]	_	_
19-32	2191-2192	,	_	_	_	_
19-33	2193-2199	extent	abstract	new	coref	23-15[154_0]
19-34	2200-2201	,	_	_	_	_
19-35	2202-2205	and	_	_	_	_
19-36	2206-2216	appearance	abstract[129]	new[129]	_	_
19-37	2217-2219	of	abstract[129]	new[129]	_	_
19-38	2220-2223	any	abstract[129]|abstract[131]	new[129]|new[131]	_	_
19-39	2224-2229	fluid	abstract[129]|substance|abstract[131]	new[129]|new|new[131]	_	_
19-40	2230-2241	collections	abstract[129]|abstract[131]	new[129]|new[131]	_	_
19-41	2242-2243	.	_	_	_	_

#Text=Blood cultures are important to evaluate for occult bloodstream infections , because LVAD patients may not present with typical signs and symptoms .
20-1	2244-2249	Blood	person|object[133]	giv|giv[133]	_	_
20-2	2250-2258	cultures	object[133]	giv[133]	_	_
20-3	2259-2262	are	_	_	_	_
20-4	2263-2272	important	_	_	_	_
20-5	2273-2275	to	_	_	_	_
20-6	2276-2284	evaluate	_	_	_	_
20-7	2285-2288	for	_	_	_	_
20-8	2289-2295	occult	event[135]	giv[135]	coref	22-10[148_135]
20-9	2296-2307	bloodstream	object|event[135]	new|giv[135]	coref	36-1
20-10	2308-2318	infections	event[135]	giv[135]	_	_
20-11	2319-2320	,	_	_	_	_
20-12	2321-2328	because	_	_	_	_
20-13	2329-2333	LVAD	abstract|person[137]	giv|giv[137]	coref|coref	23-30|25-31[174_137]
20-14	2334-2342	patients	person[137]	giv[137]	_	_
20-15	2343-2346	may	_	_	_	_
20-16	2347-2350	not	_	_	_	_
20-17	2351-2358	present	_	_	_	_
20-18	2359-2363	with	_	_	_	_
20-19	2364-2371	typical	abstract[138]	new[138]	_	_
20-20	2372-2377	signs	abstract[138]	new[138]	_	_
20-21	2378-2381	and	_	_	_	_
20-22	2382-2390	symptoms	abstract	new	_	_
20-23	2391-2392	.	_	_	_	_

#Text=Typical pathogens are skin flora like coagulase-negative Staphylococci and Staphylococcus aureus .
21-1	2393-2400	Typical	plant[140]	new[140]	coref	21-4[142_140]
21-2	2401-2410	pathogens	plant[140]	new[140]	_	_
21-3	2411-2414	are	_	_	_	_
21-4	2415-2419	skin	object|plant[142]	giv|giv[142]	_	_
21-5	2420-2425	flora	plant[142]	giv[142]	_	_
21-6	2426-2430	like	plant[142]	giv[142]	_	_
21-7	2431-2449	coagulase-negative	plant[142]|substance[143]	giv[142]|new[143]	_	_
21-8	2450-2463	Staphylococci	plant[142]|substance[143]	giv[142]|new[143]	_	_
21-9	2464-2467	and	plant[142]	giv[142]	_	_
21-10	2468-2482	Staphylococcus	plant[142]|abstract	giv[142]|new	_	_
21-11	2483-2489	aureus	plant[142]	giv[142]	_	_
21-12	2490-2491	.	_	_	_	_

#Text=Gram-negative organisms like Pseudomonas spp. and Enterobacteriaceae , and fungal infections can also occur .
22-1	2492-2505	Gram-negative	animal[145]	new[145]	coref	24-16[163_145]
22-2	2506-2515	organisms	animal[145]	new[145]	_	_
22-3	2516-2520	like	animal[145]	new[145]	_	_
22-4	2521-2532	Pseudomonas	animal[145]|place	new[145]|new	coref	29-10
22-5	2533-2537	spp.	animal[145]	new[145]	_	_
22-6	2538-2541	and	animal[145]	new[145]	_	_
22-7	2542-2560	Enterobacteriaceae	animal[145]|animal	new[145]|new	_	_
22-8	2561-2562	,	_	_	_	_
22-9	2563-2566	and	_	_	_	_
22-10	2567-2573	fungal	event[148]	giv[148]	coref	24-13[162_148]
22-11	2574-2584	infections	event[148]	giv[148]	_	_
22-12	2585-2588	can	_	_	_	_
22-13	2589-2593	also	_	_	_	_
22-14	2594-2599	occur	_	_	_	_
22-15	2600-2601	.	_	_	_	_

#Text=Surgical evaluation for debridement of the driveline exit site may be needed depending on the extent of the infection , and should be performed by a surgical team with LVAD experience .
23-1	2602-2610	Surgical	abstract[149]	new[149]	_	_
23-2	2611-2621	evaluation	abstract[149]	new[149]	_	_
23-3	2622-2625	for	abstract[149]	new[149]	_	_
23-4	2626-2637	debridement	abstract[149]|event[150]	new[149]|new[150]	coref	28-16[190_150]
23-5	2638-2640	of	abstract[149]|event[150]	new[149]|new[150]	_	_
23-6	2641-2644	the	abstract[149]|event[150]|place[153]	new[149]|new[150]|giv[153]	_	_
23-7	2645-2654	driveline	abstract[149]|event[150]|abstract|place[153]	new[149]|new[150]|giv|giv[153]	_	_
23-8	2655-2659	exit	abstract[149]|event[150]|abstract|place[153]	new[149]|new[150]|giv|giv[153]	_	_
23-9	2660-2664	site	abstract[149]|event[150]|place[153]	new[149]|new[150]|giv[153]	_	_
23-10	2665-2668	may	_	_	_	_
23-11	2669-2671	be	_	_	_	_
23-12	2672-2678	needed	_	_	_	_
23-13	2679-2688	depending	_	_	_	_
23-14	2689-2691	on	_	_	_	_
23-15	2692-2695	the	abstract[154]	giv[154]	_	_
23-16	2696-2702	extent	abstract[154]	giv[154]	_	_
23-17	2703-2705	of	abstract[154]	giv[154]	_	_
23-18	2706-2709	the	abstract[154]|abstract[155]	giv[154]|giv[155]	coref	25-28[173_155]
23-19	2710-2719	infection	abstract[154]|abstract[155]	giv[154]|giv[155]	_	_
23-20	2720-2721	,	_	_	_	_
23-21	2722-2725	and	_	_	_	_
23-22	2726-2732	should	_	_	_	_
23-23	2733-2735	be	_	_	_	_
23-24	2736-2745	performed	_	_	_	_
23-25	2746-2748	by	_	_	_	_
23-26	2749-2750	a	person[156]	giv[156]	_	_
23-27	2751-2759	surgical	person[156]	giv[156]	_	_
23-28	2760-2764	team	person[156]	giv[156]	_	_
23-29	2765-2769	with	person[156]	giv[156]	_	_
23-30	2770-2774	LVAD	person[156]|abstract|abstract[158]	giv[156]|giv|new[158]	coref	32-6
23-31	2775-2785	experience	person[156]|abstract[158]	giv[156]|new[158]	_	_
23-32	2786-2787	.	_	_	_	_

#Text=Infectious diseases consultation may be needed , particularly in the case of polymicrobial infections or multidrug-resistant organisms .
24-1	2788-2798	Infectious	abstract[160]	new[160]	_	_
24-2	2799-2807	diseases	abstract|abstract[160]	new|new[160]	_	_
24-3	2808-2820	consultation	abstract[160]	new[160]	_	_
24-4	2821-2824	may	_	_	_	_
24-5	2825-2827	be	_	_	_	_
24-6	2828-2834	needed	_	_	_	_
24-7	2835-2836	,	_	_	_	_
24-8	2837-2849	particularly	abstract[161]	new[161]	_	_
24-9	2850-2852	in	abstract[161]	new[161]	_	_
24-10	2853-2856	the	abstract[161]	new[161]	_	_
24-11	2857-2861	case	abstract[161]	new[161]	_	_
24-12	2862-2864	of	abstract[161]	new[161]	_	_
24-13	2865-2878	polymicrobial	abstract[161]|event[162]	new[161]|giv[162]	coref	27-1[183_162]
24-14	2879-2889	infections	abstract[161]|event[162]	new[161]|giv[162]	_	_
24-15	2890-2892	or	abstract[161]|event[162]	new[161]|giv[162]	_	_
24-16	2893-2912	multidrug-resistant	abstract[161]|event[162]|animal[163]	new[161]|giv[162]|giv[163]	_	_
24-17	2913-2922	organisms	abstract[161]|event[162]|animal[163]	new[161]|giv[162]|giv[163]	_	_
24-18	2923-2924	.	_	_	_	_

#Text=If bacteremia or sepsis are present , a chest and abdomen CT , transthoracic and even transesophageal echocardiogram should be obtained to evaluate for the source of the infection ( especially in patients with pacemaker or defibrillator leads ) .
25-1	2925-2927	If	_	_	_	_
25-2	2928-2938	bacteremia	abstract	new	_	_
25-3	2939-2941	or	_	_	_	_
25-4	2942-2948	sepsis	abstract	new	_	_
25-5	2949-2952	are	_	_	_	_
25-6	2953-2960	present	_	_	_	_
25-7	2961-2962	,	_	_	_	_
25-8	2963-2964	a	object[166]	new[166]	_	_
25-9	2965-2970	chest	object[166]	new[166]	_	_
25-10	2971-2974	and	_	_	_	_
25-11	2975-2982	abdomen	place|abstract[168]	new|giv[168]	_	_
25-12	2983-2985	CT	abstract[168]	giv[168]	_	_
25-13	2986-2987	,	_	_	_	_
25-14	2988-3001	transthoracic	object	new	_	_
25-15	3002-3005	and	_	_	_	_
25-16	3006-3010	even	abstract[171]	new[171]	_	_
25-17	3011-3026	transesophageal	abstract|abstract[171]	new|new[171]	_	_
25-18	3027-3041	echocardiogram	abstract[171]	new[171]	_	_
25-19	3042-3048	should	_	_	_	_
25-20	3049-3051	be	_	_	_	_
25-21	3052-3060	obtained	_	_	_	_
25-22	3061-3063	to	_	_	_	_
25-23	3064-3072	evaluate	_	_	_	_
25-24	3073-3076	for	_	_	_	_
25-25	3077-3080	the	abstract[172]	new[172]	_	_
25-26	3081-3087	source	abstract[172]	new[172]	_	_
25-27	3088-3090	of	abstract[172]	new[172]	_	_
25-28	3091-3094	the	abstract[172]|abstract[173]	new[172]|giv[173]	coref	29-10[194_173]
25-29	3095-3104	infection	abstract[172]|abstract[173]	new[172]|giv[173]	_	_
25-30	3105-3106	(	_	_	_	_
25-31	3107-3117	especially	person[174]	giv[174]	coref	31-37[0_174]
25-32	3118-3120	in	person[174]	giv[174]	_	_
25-33	3121-3129	patients	person[174]	giv[174]	_	_
25-34	3130-3134	with	person[174]	giv[174]	_	_
25-35	3135-3144	pacemaker	person[174]|object	giv[174]|new	_	_
25-36	3145-3147	or	person[174]	giv[174]	_	_
25-37	3148-3161	defibrillator	person[174]|abstract|abstract[177]	giv[174]|new|new[177]	_	_
25-38	3162-3167	leads	person[174]|abstract[177]	giv[174]|new[177]	_	_
25-39	3168-3169	)	_	_	_	_
25-40	3170-3171	.	_	_	_	_

#Text=There is an emerging role for PET imaging with F-18 labeled fluoro-2-deoxyglucose .
26-1	3172-3177	There	_	_	_	_
26-2	3178-3180	is	_	_	_	_
26-3	3181-3183	an	abstract[178]	new[178]	coref	30-1[197_178]
26-4	3184-3192	emerging	abstract[178]	new[178]	_	_
26-5	3193-3197	role	abstract[178]	new[178]	_	_
26-6	3198-3201	for	abstract[178]	new[178]	_	_
26-7	3202-3205	PET	abstract[178]|animal	new[178]|giv	_	_
26-8	3206-3213	imaging	_	_	_	_
26-9	3214-3218	with	_	_	_	_
26-10	3219-3223	F-18	object	new	_	_
26-11	3224-3231	labeled	_	_	_	_
26-12	3232-3253	fluoro-2-deoxyglucose	object	new	_	_
26-13	3254-3255	.	_	_	_	_

#Text=VAD infections are biofilm-based and difficult to eradicate .
27-1	3256-3259	VAD	object|event[183]	new|giv[183]	coref|coref	28-4|28-4[187_183]
27-2	3260-3270	infections	event[183]	giv[183]	_	_
27-3	3271-3274	are	_	_	_	_
27-4	3275-3288	biofilm-based	_	_	_	_
27-5	3289-3292	and	_	_	_	_
27-6	3293-3302	difficult	_	_	_	_
27-7	3303-3305	to	_	_	_	_
27-8	3306-3315	eradicate	_	_	_	_
27-9	3316-3317	.	_	_	_	_

#Text=Treatment strategies for VAD infections include intravenous antibiotics followed by oral suppression in tandem with surgical debridement .
28-1	3318-3327	Treatment	person|abstract[185]	new|new[185]	_	_
28-2	3328-3338	strategies	abstract[185]	new[185]	_	_
28-3	3339-3342	for	abstract[185]	new[185]	_	_
28-4	3343-3346	VAD	abstract[185]|object|event[187]	new[185]|giv|giv[187]	coref	29-1[0_187]
28-5	3347-3357	infections	abstract[185]|event[187]	new[185]|giv[187]	_	_
28-6	3358-3365	include	_	_	_	_
28-7	3366-3377	intravenous	substance[188]	new[188]	_	_
28-8	3378-3389	antibiotics	substance[188]	new[188]	_	_
28-9	3390-3398	followed	_	_	_	_
28-10	3399-3401	by	_	_	_	_
28-11	3402-3406	oral	abstract[189]	new[189]	_	_
28-12	3407-3418	suppression	abstract[189]	new[189]	_	_
28-13	3419-3421	in	abstract[189]	new[189]	_	_
28-14	3422-3428	tandem	abstract[189]	new[189]	_	_
28-15	3429-3433	with	abstract[189]	new[189]	_	_
28-16	3434-3442	surgical	abstract[189]|event[190]	new[189]|giv[190]	coref	29-7[0_190]
28-17	3443-3454	debridement	abstract[189]|event[190]	new[189]|giv[190]	_	_
28-18	3455-3456	.	_	_	_	_

#Text=Infections tend to be recurrent despite debridement , with Pseudomonas infection in particular , showing a lower success rate .
29-1	3457-3467	Infections	event	giv	coref	32-6[214_0]
29-2	3468-3472	tend	_	_	_	_
29-3	3473-3475	to	_	_	_	_
29-4	3476-3478	be	_	_	_	_
29-5	3479-3488	recurrent	_	_	_	_
29-6	3489-3496	despite	_	_	_	_
29-7	3497-3508	debridement	event	giv	_	_
29-8	3509-3510	,	_	_	_	_
29-9	3511-3515	with	_	_	_	_
29-10	3516-3527	Pseudomonas	object|abstract[194]	giv|giv[194]	coref	33-9[0_194]
29-11	3528-3537	infection	abstract[194]	giv[194]	_	_
29-12	3538-3540	in	abstract[194]	giv[194]	_	_
29-13	3541-3551	particular	abstract[194]	giv[194]	_	_
29-14	3552-3553	,	_	_	_	_
29-15	3554-3561	showing	_	_	_	_
29-16	3562-3563	a	quantity[196]	new[196]	coref	33-5[221_196]
29-17	3564-3569	lower	quantity[196]	new[196]	_	_
29-18	3570-3577	success	abstract|quantity[196]	new|new[196]	_	_
29-19	3578-3582	rate	quantity[196]	new[196]	_	_
29-20	3583-3584	.	_	_	_	_

#Text=The role of pump exchange is not clearly defined .
30-1	3585-3588	The	abstract[197]	giv[197]	_	_
30-2	3589-3593	role	abstract[197]	giv[197]	_	_
30-3	3594-3596	of	abstract[197]	giv[197]	_	_
30-4	3597-3601	pump	abstract[197]|object|abstract[199]	giv[197]|giv|new[199]	coref|coref	31-26|31-26[208_199]
30-5	3602-3610	exchange	abstract[197]|abstract[199]	giv[197]|new[199]	_	_
30-6	3611-3613	is	_	_	_	_
30-7	3614-3617	not	_	_	_	_
30-8	3618-3625	clearly	_	_	_	_
30-9	3626-3633	defined	_	_	_	_
30-10	3634-3635	.	_	_	_	_

#Text=One study noted a particularly poor prognosis with candidemia and concomitant presence of a cardiac-implanted electronic device , and failure to remove the device during pump exchange was associated with poor outcomes in 65 % of patients .
31-1	3636-3639	One	abstract[200]	new[200]	coref	33-1[218_200]
31-2	3640-3645	study	abstract[200]	new[200]	_	_
31-3	3646-3651	noted	_	_	_	_
31-4	3652-3653	a	abstract[201]	new[201]	_	_
31-5	3654-3666	particularly	abstract[201]	new[201]	_	_
31-6	3667-3671	poor	abstract[201]	new[201]	_	_
31-7	3672-3681	prognosis	abstract[201]	new[201]	_	_
31-8	3682-3686	with	abstract[201]	new[201]	_	_
31-9	3687-3697	candidemia	abstract[201]|event	new[201]|new	_	_
31-10	3698-3701	and	_	_	_	_
31-11	3702-3713	concomitant	abstract[203]	new[203]	_	_
31-12	3714-3722	presence	abstract[203]	new[203]	_	_
31-13	3723-3725	of	abstract[203]	new[203]	_	_
31-14	3726-3727	a	abstract[203]|object[204]	new[203]|new[204]	coref	31-23[206_204]
31-15	3728-3745	cardiac-implanted	abstract[203]|object[204]	new[203]|new[204]	_	_
31-16	3746-3756	electronic	abstract[203]|object[204]	new[203]|new[204]	_	_
31-17	3757-3763	device	abstract[203]|object[204]	new[203]|new[204]	_	_
31-18	3764-3765	,	_	_	_	_
31-19	3766-3769	and	_	_	_	_
31-20	3770-3777	failure	event	new	coref	35-28
31-21	3778-3780	to	_	_	_	_
31-22	3781-3787	remove	_	_	_	_
31-23	3788-3791	the	object[206]	giv[206]	_	_
31-24	3792-3798	device	object[206]	giv[206]	_	_
31-25	3799-3805	during	object[206]	giv[206]	_	_
31-26	3806-3810	pump	object[206]|object|event[208]	giv[206]|giv|giv[208]	coref|coref	35-13|35-24[236_208]
31-27	3811-3819	exchange	object[206]|event[208]	giv[206]|giv[208]	_	_
31-28	3820-3823	was	_	_	_	_
31-29	3824-3834	associated	_	_	_	_
31-30	3835-3839	with	_	_	_	_
31-31	3840-3844	poor	event[209]	new[209]	coref	37-21[248_209]
31-32	3845-3853	outcomes	event[209]	new[209]	_	_
31-33	3854-3856	in	event[209]	new[209]	_	_
31-34	3857-3859	65	event[209]|quantity[210]	new[209]|new[210]	_	_
31-35	3860-3861	%	event[209]|quantity[210]	new[209]|new[210]	_	_
31-36	3862-3864	of	event[209]|quantity[210]	new[209]|new[210]	_	_
31-37	3865-3873	patients	event[209]|quantity[210]|person	new[209]|new[210]|giv	coref	34-4[225_0]
31-38	3874-3875	.	_	_	_	_

#Text=Some studies have shown that LVAD infections adversely affect survival after adjusting for age and comorbidities .
32-1	3876-3880	Some	event[212]	giv[212]	_	_
32-2	3881-3888	studies	event[212]	giv[212]	_	_
32-3	3889-3893	have	_	_	_	_
32-4	3894-3899	shown	_	_	_	_
32-5	3900-3904	that	_	_	_	_
32-6	3905-3909	LVAD	object|event[214]	giv|giv[214]	coref|coref	34-6[0_214]|35-4
32-7	3910-3920	infections	event[214]	giv[214]	_	_
32-8	3921-3930	adversely	_	_	_	_
32-9	3931-3937	affect	_	_	_	_
32-10	3938-3946	survival	event	new	_	_
32-11	3947-3952	after	_	_	_	_
32-12	3953-3962	adjusting	_	_	_	_
32-13	3963-3966	for	_	_	_	_
32-14	3967-3970	age	abstract	giv	_	_
32-15	3971-3974	and	_	_	_	_
32-16	3975-3988	comorbidities	abstract	new	_	_
32-17	3989-3990	.	_	_	_	_

#Text=One prospective study showed a 22 % overall infection rate of LVADs and a 5.6-times greater
33-1	3991-3994	One	abstract[218]	giv[218]	_	_
33-2	3995-4006	prospective	abstract[218]	giv[218]	_	_
33-3	4007-4012	study	abstract[218]	giv[218]	_	_
33-4	4013-4019	showed	_	_	_	_
33-5	4020-4021	a	quantity[221]	giv[221]	_	_
33-6	4022-4024	22	quantity[219]|quantity[221]	new[219]|giv[221]	_	_
33-7	4025-4026	%	quantity[219]|quantity[221]	new[219]|giv[221]	_	_
33-8	4027-4034	overall	quantity[221]	giv[221]	_	_
33-9	4035-4044	infection	abstract|quantity[221]	giv|giv[221]	coref	37-8[246_0]
33-10	4045-4049	rate	quantity[221]	giv[221]	_	_
33-11	4050-4052	of	quantity[221]	giv[221]	_	_
33-12	4053-4058	LVADs	quantity[221]|abstract	giv[221]|giv	_	_
33-13	4059-4062	and	_	_	_	_
33-14	4063-4064	a	quantity[223]	new[223]	_	_
33-15	4065-4074	5.6-times	quantity[223]	new[223]	_	_
33-16	4075-4082	greater	quantity[223]	new[223]	_	_

#Text=1-year mortality in patients with infections .
34-1	4083-4089	1-year	abstract[224]	new[224]	coref	35-2[0_224]
34-2	4090-4099	mortality	abstract[224]	new[224]	_	_
34-3	4100-4102	in	abstract[224]	new[224]	_	_
34-4	4103-4111	patients	abstract[224]|person[225]	new[224]|giv[225]	_	_
34-5	4112-4116	with	abstract[224]|person[225]	new[224]|giv[225]	_	_
34-6	4117-4127	infections	abstract[224]|person[225]|event	new[224]|giv[225]|giv	coref	35-4[229_0]
34-7	4128-4129	.	_	_	_	_

#Text=Besides mortality , LVAD infections are associated with a greater risk of pump thrombosis , bleeding complications , prolonged hospitalization , need for pump exchange , and failure to achieve transplantation .
35-1	4130-4137	Besides	_	_	_	_
35-2	4138-4147	mortality	abstract	giv	coref	36-12[242_0]
35-3	4148-4149	,	_	_	_	_
35-4	4150-4154	LVAD	object|event[229]	giv|giv[229]	coref|coref	36-1[240_229]|37-9
35-5	4155-4165	infections	event[229]	giv[229]	_	_
35-6	4166-4169	are	_	_	_	_
35-7	4170-4180	associated	_	_	_	_
35-8	4181-4185	with	_	_	_	_
35-9	4186-4187	a	abstract[230]	new[230]	_	_
35-10	4188-4195	greater	abstract[230]	new[230]	_	_
35-11	4196-4200	risk	abstract[230]	new[230]	_	_
35-12	4201-4203	of	abstract[230]	new[230]	_	_
35-13	4204-4208	pump	abstract[230]|object|event[232]	new[230]|giv|new[232]	coref	35-24
35-14	4209-4219	thrombosis	abstract[230]|event[232]	new[230]|new[232]	_	_
35-15	4220-4221	,	_	_	_	_
35-16	4222-4230	bleeding	_	_	_	_
35-17	4231-4244	complications	abstract	new	coref	40-6[255_0]
35-18	4245-4246	,	_	_	_	_
35-19	4247-4256	prolonged	event[234]	new[234]	_	_
35-20	4257-4272	hospitalization	event[234]	new[234]	_	_
35-21	4273-4274	,	_	_	_	_
35-22	4275-4279	need	_	_	_	_
35-23	4280-4283	for	_	_	_	_
35-24	4284-4288	pump	object|event[236]	giv|giv[236]	_	_
35-25	4289-4297	exchange	event[236]	giv[236]	_	_
35-26	4298-4299	,	_	_	_	_
35-27	4300-4303	and	_	_	_	_
35-28	4304-4311	failure	abstract	giv	_	_
35-29	4312-4314	to	_	_	_	_
35-30	4315-4322	achieve	_	_	_	_
35-31	4323-4338	transplantation	event	new	_	_
35-32	4339-4340	.	_	_	_	_

#Text=Bloodstream infections , in particular , are associated with stroke and increased mortality .
36-1	4341-4352	Bloodstream	substance|event[240]	giv|giv[240]	_	_
36-2	4353-4363	infections	event[240]	giv[240]	_	_
36-3	4364-4365	,	event[240]	giv[240]	_	_
36-4	4366-4368	in	event[240]	giv[240]	_	_
36-5	4369-4379	particular	event[240]	giv[240]	_	_
36-6	4380-4381	,	_	_	_	_
36-7	4382-4385	are	_	_	_	_
36-8	4386-4396	associated	_	_	_	_
36-9	4397-4401	with	_	_	_	_
36-10	4402-4408	stroke	event	new	_	_
36-11	4409-4412	and	_	_	_	_
36-12	4413-4422	increased	abstract[242]	giv[242]	_	_
36-13	4423-4432	mortality	abstract[242]	giv[242]	_	_
36-14	4433-4434	.	_	_	_	_

#Text=Despite these risks , the presence of an LVAD infection has not been shown to have a negative impact on post-transplant outcomes .
37-1	4435-4442	Despite	_	_	_	_
37-2	4443-4448	these	abstract[243]	new[243]	_	_
37-3	4449-4454	risks	abstract[243]	new[243]	_	_
37-4	4455-4456	,	_	_	_	_
37-5	4457-4460	the	abstract[244]	new[244]	_	_
37-6	4461-4469	presence	abstract[244]	new[244]	_	_
37-7	4470-4472	of	abstract[244]	new[244]	_	_
37-8	4473-4475	an	abstract[244]|abstract[246]	new[244]|giv[246]	_	_
37-9	4476-4480	LVAD	abstract[244]|object|abstract[246]	new[244]|giv|giv[246]	coref	40-11
37-10	4481-4490	infection	abstract[244]|abstract[246]	new[244]|giv[246]	_	_
37-11	4491-4494	has	_	_	_	_
37-12	4495-4498	not	_	_	_	_
37-13	4499-4503	been	_	_	_	_
37-14	4504-4509	shown	_	_	_	_
37-15	4510-4512	to	_	_	_	_
37-16	4513-4517	have	_	_	_	_
37-17	4518-4519	a	abstract[247]	new[247]	_	_
37-18	4520-4528	negative	abstract[247]	new[247]	_	_
37-19	4529-4535	impact	abstract[247]	new[247]	_	_
37-20	4536-4538	on	abstract[247]	new[247]	_	_
37-21	4539-4554	post-transplant	abstract[247]|event[248]	new[247]|giv[248]	_	_
37-22	4555-4563	outcomes	abstract[247]|event[248]	new[247]|giv[248]	_	_
37-23	4564-4565	.	_	_	_	_

#Text=8.2 .
38-1	4566-4569	8.2	abstract	new	_	_
38-2	4570-4571	.	_	_	_	_

#Text=Gastrointestinal ( GI ) Bleed
39-1	4572-4588	Gastrointestinal	person	new	_	_
39-2	4589-4590	(	_	_	_	_
39-3	4591-4593	GI	abstract	new	coref	40-1
39-4	4594-4595	)	_	_	_	_
39-5	4596-4601	Bleed	_	_	_	_

#Text=GI bleed is one of the most frequent complications after LVAD implant and the most common reason for hospital readmission .
40-1	4602-4604	GI	abstract|event[253]	giv|new[253]	_	_
40-2	4605-4610	bleed	event[253]	new[253]	_	_
40-3	4611-4613	is	_	_	_	_
40-4	4614-4617	one	abstract[254]	new[254]	_	_
40-5	4618-4620	of	abstract[254]	new[254]	_	_
40-6	4621-4624	the	abstract[254]|abstract[255]	new[254]|giv[255]	_	_
40-7	4625-4629	most	abstract[254]|abstract[255]	new[254]|giv[255]	_	_
40-8	4630-4638	frequent	abstract[254]|abstract[255]	new[254]|giv[255]	_	_
40-9	4639-4652	complications	abstract[254]|abstract[255]	new[254]|giv[255]	_	_
40-10	4653-4658	after	abstract[254]|abstract[255]	new[254]|giv[255]	_	_
40-11	4659-4663	LVAD	abstract[254]|abstract[255]|abstract|object[257]	new[254]|giv[255]|giv|new[257]	coref	42-20
40-12	4664-4671	implant	abstract[254]|abstract[255]|object[257]	new[254]|giv[255]|new[257]	_	_
40-13	4672-4675	and	_	_	_	_
40-14	4676-4679	the	abstract[258]	new[258]	ana	41-1[0_258]
40-15	4680-4684	most	abstract[258]	new[258]	_	_
40-16	4685-4691	common	abstract[258]	new[258]	_	_
40-17	4692-4698	reason	abstract[258]	new[258]	_	_
40-18	4699-4702	for	abstract[258]	new[258]	_	_
40-19	4703-4711	hospital	abstract[258]|place|abstract[260]	new[258]|new|new[260]	_	_
40-20	4712-4723	readmission	abstract[258]|abstract[260]	new[258]|new[260]	_	_
40-21	4724-4725	.	_	_	_	_

#Text=It is triggered by the use of antiplatelet and anticoagulant therapy .
41-1	4726-4728	It	abstract	giv	_	_
41-2	4729-4731	is	_	_	_	_
41-3	4732-4741	triggered	_	_	_	_
41-4	4742-4744	by	_	_	_	_
41-5	4745-4748	the	abstract[262]	new[262]	_	_
41-6	4749-4752	use	abstract[262]	new[262]	_	_
41-7	4753-4755	of	abstract[262]	new[262]	_	_
41-8	4756-4768	antiplatelet	abstract[262]|substance	new[262]|new	_	_
41-9	4769-4772	and	_	_	_	_
41-10	4773-4786	anticoagulant	abstract|abstract[265]	new|new[265]	_	_
41-11	4787-4794	therapy	abstract[265]	new[265]	_	_
41-12	4795-4796	.	_	_	_	_

#Text=Additionally , CF-LVADs can cause acquired von Willebrand factor deficiency due to the high shear stress imposed by the LVAD motor , resulting in breakdown of large von Willebrand factor multimers .
42-1	4797-4809	Additionally	_	_	_	_
42-2	4810-4811	,	_	_	_	_
42-3	4812-4820	CF-LVADs	substance	new	_	_
42-4	4821-4824	can	_	_	_	_
42-5	4825-4830	cause	_	_	_	_
42-6	4831-4839	acquired	_	_	_	_
42-7	4840-4843	von	abstract	new	coref	42-28
42-8	4844-4854	Willebrand	substance|abstract[270]	new|new[270]	coref	42-29
42-9	4855-4861	factor	abstract|abstract[270]	new|new[270]	coref	42-28[278_0]
42-10	4862-4872	deficiency	abstract[270]	new[270]	_	_
42-11	4873-4876	due	_	_	_	_
42-12	4877-4879	to	_	_	_	_
42-13	4880-4883	the	abstract[272]	new[272]	_	_
42-14	4884-4888	high	abstract[272]	new[272]	_	_
42-15	4889-4894	shear	place|abstract[272]	new|new[272]	_	_
42-16	4895-4901	stress	abstract[272]	new[272]	_	_
42-17	4902-4909	imposed	_	_	_	_
42-18	4910-4912	by	_	_	_	_
42-19	4913-4916	the	abstract[274]	new[274]	_	_
42-20	4917-4921	LVAD	place|abstract[274]	giv|new[274]	_	_
42-21	4922-4927	motor	abstract[274]	new[274]	_	_
42-22	4928-4929	,	_	_	_	_
42-23	4930-4939	resulting	_	_	_	_
42-24	4940-4942	in	_	_	_	_
42-25	4943-4952	breakdown	event[275]	new[275]	_	_
42-26	4953-4955	of	event[275]	new[275]	_	_
42-27	4956-4961	large	event[275]|object[279]	new[275]|new[279]	_	_
42-28	4962-4965	von	event[275]|abstract|abstract[278]|object[279]	new[275]|giv|giv[278]|new[279]	_	_
42-29	4966-4976	Willebrand	event[275]|abstract|abstract[278]|object[279]	new[275]|giv|giv[278]|new[279]	_	_
42-30	4977-4983	factor	event[275]|abstract[278]|object[279]	new[275]|giv[278]|new[279]	_	_
42-31	4984-4993	multimers	event[275]|object[279]	new[275]|new[279]	_	_
42-32	4994-4995	.	_	_	_	_

#Text=Also , continuous flow physiology and dysregulation of angiogenic factors have been shown to lead to development of arteriovenous malformations ( AVMs ) in the gastrointestinal tract , nasopharynx , brain , and other tissues .
43-1	4996-5000	Also	_	_	_	_
43-2	5001-5002	,	_	_	_	_
43-3	5003-5013	continuous	abstract[281]	new[281]	_	_
43-4	5014-5018	flow	abstract|abstract[281]	new|new[281]	_	_
43-5	5019-5029	physiology	abstract[281]	new[281]	_	_
43-6	5030-5033	and	_	_	_	_
43-7	5034-5047	dysregulation	abstract[282]	new[282]	_	_
43-8	5048-5050	of	abstract[282]	new[282]	_	_
43-9	5051-5061	angiogenic	abstract[282]|abstract|abstract[284]	new[282]|new|new[284]	_	_
43-10	5062-5069	factors	abstract[282]|abstract[284]	new[282]|new[284]	_	_
43-11	5070-5074	have	_	_	_	_
43-12	5075-5079	been	_	_	_	_
43-13	5080-5085	shown	_	_	_	_
43-14	5086-5088	to	_	_	_	_
43-15	5089-5093	lead	_	_	_	_
43-16	5094-5096	to	_	_	_	_
43-17	5097-5108	development	event[285]	new[285]	_	_
43-18	5109-5111	of	event[285]	new[285]	_	_
43-19	5112-5125	arteriovenous	event[285]|person|abstract[287]	new[285]|new|new[287]	appos	43-22[0_287]
43-20	5126-5139	malformations	event[285]|abstract[287]	new[285]|new[287]	_	_
43-21	5140-5141	(	_	_	_	_
43-22	5142-5146	AVMs	abstract	giv	_	_
43-23	5147-5148	)	_	_	_	_
43-24	5149-5151	in	_	_	_	_
43-25	5152-5155	the	object[289]	new[289]	_	_
43-26	5156-5172	gastrointestinal	object[289]	new[289]	_	_
43-27	5173-5178	tract	object[289]	new[289]	_	_
43-28	5179-5180	,	_	_	_	_
43-29	5181-5192	nasopharynx	place	new	_	_
43-30	5193-5194	,	_	_	_	_
43-31	5195-5200	brain	object	new	_	_
43-32	5201-5202	,	_	_	_	_
43-33	5203-5206	and	_	_	_	_
43-34	5207-5212	other	place[292]	new[292]	_	_
43-35	5213-5220	tissues	place[292]	new[292]	_	_
43-36	5221-5222	.	_	_	_	_
